Species/Strain: Mouse/B6C3F1

Test Type: 90-DAY

Route: GAVAGE

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 10/22/2014 AVERAGE SEVERITY GRADES[b]

Test Compound: 2',3'-Dideoxycytidine

CAS Number: 7481-89-2

First Dose M/F: NA / NA

Time Report Requested: 02:46:16

Lab: SRI

C Number: C88073B

Lock Date: 02/05/1993

Cage Range: ΑII

Date Range: ΑII

Reasons For Removal: ΑII

Removal Date Range: ΑII

Treatment Groups: ΑII

Female **Study Gender:**

PWG Approval Date NONE

Test Type: 90-DAY

Route: GAVAGE

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b] Date Report Requested: 10/22/2014 Time Report Requested: 02:46:16

Test Compound: 2',3'-Dideoxycytidine

CAS Number: 7481-89-2

First Dose M/F: NA / NA

Time Report Requested: 02:46:16

Lab: SRI

Species/Strain: Mouse/B6C3F1

B6C3F1 Mouse FEMALE	VEHICLE CONTROL	500 MG/KG	1000 MG/KG
Disposition Summary			
Animals Initially In Study	50	50	50
Early Deaths			
Moribund Sacrifice			3
Natural Death			3
Survivors			
Terminal Sacrifice	50	50	44
Animals Examined Microscopically	50	50	50
ALIMENTARY SYSTEM			
Esophagus	(50)	(50)	(48)
Gallbladder	(48)	(49)	(49)
Intestine Large, Cecum	(50)	(50)	(50)
Intestine Large, Colon	(50)	(49)	(50)
Intestine Large, Rectum	(50)	(50)	(50)
Intestine Small, Duodenum	(49)	(49)	(48)
Intestine Small, Ileum	(49)	(48)	(47)
Intestine Small, Jejunum	(47)	(50)	(50)
Liver	(50)	(50)	(50)
Basophilic Focus	2		
Hepatocyte, Vacuolization Cytoplasmic			2 [4.0]
Inflammation, Chronic	1 [1.0]		1 [1.0]
Mesentery	(1)	(0)	(0)
Accessory Spleen	1		
Pancreas	(50)	(50)	(50)
Salivary Glands	(50)	(50)	(50)
Infiltration Cellular, Lymphocyte	4 [2.3]	4 [2.0]	1 [2.0]
Stomach, Forestomach	(50)	(50)	(50)
Epithelium, Hyperplasia			7 [2.9]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Species/Strain: Mouse/B6C3F1

Test Type: 90-DAY

Route: GAVAGE

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b] Date Report Requested: 10/22/2014 Time Report Requested: 02:46:16

Test Compound: 2',3'-Dideoxycytidine

CAS Number: 7481-89-2

Time Report Requested: 02:46:16

First Dose M/F: NA / NA

Lab: SRI

B6C3F1 Mouse FEMALE	VEHICLE CONTROL	500 MG/KG	1000 MG/KG
Ulcer			3 [2.3]
Stomach, Glandular	(50)	(50)	(50)
Ulcer			1 [3.0]
CARDIOVASCULAR SYSTEM			
Blood Vessel	(50)	(50)	(50)
Heart	(50)	(50)	(50)
Cardiomyopathy		1 [2.0]	
ENDOCRINE SYSTEM			
Adrenal Cortex	(50)	(50)	(50)
Accessory Adrenal Cortical Nodule	2 [2.0]	6 [2.0]	4 [1.8]
Adrenal Medulla	(50)	(50)	(50)
Islets, Pancreatic	(50)	(50)	(50)
Parathyroid Gland	(47)	(47)	(45)
Cyst	2 [3.0]	4 [3.0]	
Pituitary Gland	(47)	(50)	(48)
Pars Nervosa, Cyst		1 [2.0]	
Thyroid Gland	(50)	(50)	(50)
Degeneration, Cystic	4 [1.5]	4 [1.8]	10 [1.7]
Follicle, Cyst			1 [2.0]
GENERAL BODY SYSTEM None			
GENITAL SYSTEM			
Clitoral Gland	(50)	(50)	(50)
Ovary	(50)	(50)	(50)
Cyst	3 [3.0]	1 [3.0]	2 [3.0]
Uterus	(50)	(50)	(50)
Hyperplasia, Cystic	34 [2.0]	26 [1.9]	31 [1.8]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Species/Strain: Mouse/B6C3F1

Test Type: 90-DAY

Route: GAVAGE

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b] Date Report Requested: 10/22/2014 Time Report Requested: 02:46:16

Test Compound: 2',3'-Dideoxycytidine

CAS Number: 7481-89-2

Time Report Requested: 02:46:16 First Dose M/F: NA / NA

Lab: SRI

B6C3F1 Mouse FEMALE	VEHICLE CONTROL	500 MG/KG	1000 MG/KG
HEMATOPOIETIC SYSTEM			
Bone Marrow	(50)	(50)	(50)
Hyperplasia	1 [2.0]		
Lymph Node	(0)	(0)	(5)
Lymph Node, Mandibular	(49)	(49)	(47)
Lymph Node, Mesenteric	(49)	(50)	(47)
Spleen	(50)	(50)	(50)
Hematopoietic Cell Proliferation	2 [2.5]		1 [2.0]
Thymus	(49)	(49)	(47)
Atrophy			1 [2.0]
INTEGUMENTARY SYSTEM			
Mammary Gland	(50)	(50)	(49)
Skin	(50)	(50)	(50)
Epidermis, Hyperplasia	1 [1.0]	4 [2.0]	
Inflammation, Chronic	1 [1.0]	3 [1.3]	
MUSCULOSKELETAL SYSTEM			
Bone	(50)	(50)	(50)
Skeletal Muscle	(0)	(0)	(1)
NERVOUS SYSTEM			
Brain	(50)	(50)	(50)
Peripheral Nerve	(0)	(1)	(0)
Spinal Cord	(0)	(1)	(0)
RESPIRATORY SYSTEM			
Lung	(50)	(50)	(50)
Alveolar Epith, Hyperplasia		1 [4.0]	
Hemorrhage	1 [2.0]	1 [2.0]	2 [2.0]
Inflammation, Granulomatous		1 [3.0]	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Species/Strain: Mouse/B6C3F1

Test Type: 90-DAY

Route: GAVAGE

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b] Date Report Requested: 10/22/2014 Time Report Requested: 02:46:16

Test Compound: 2',3'-Dideoxycytidine

CAS Number: 7481-89-2

Time Report Requested: 02:46:16

First Dose M/F: NA / NA

Lab: SRI

B6C3F1 Mouse FEMALE	VEHICLE CONTROL	500 MG/KG	1000 MG/KG
Nose	(50)	(50)	(50)
Trachea	(50)	(50)	(50)
SPECIAL SENSES SYSTEM			
Ear	(0)	(1)	(0)
URINARY SYSTEM			
Kidney	(50)	(50)	(50)
Casts Protein	3 [1.0]	7 [1.0]	9 [1.0]
Renal Tubule, Atrophy		1 [4.0]	
Renal Tubule, Necrosis			1 [2.0]
Renal Tubule, Regeneration	3 [1.3]	1 [1.0]	2 [1.0]
Urinary Bladder	(49)	(50)	(50)

^{**} END OF REPORT **

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)